Articles from ViroCell Biologics

ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. (“AvenCell”), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases.

ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces the opening of a University College London (“UCL”) clinical trial to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL). Dr. Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of Child Health, Director of the BMT/CART unit at Great Ormond Street Hospital and an international leader in CAR T-cell therapy for paediatric ALL.

ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the appointment of James Miskin as a Special Advisor. James will leverage expertise gained from a 25-year career in CGT to support ViroCell’s continued growth and technical development.

ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the expansion of the Company’s U.S. business development team with the appointments of Meredith Brown, as Senior Director, and Elaine Rihn as Director of Business Development. Both join from Lonza Inc., a global CDMO, where their roles focused on generating and expanding commercial contracts with clients in CGT manufacturing. Meredith and Elaine will focus on growing ViroCell’s U.S. market share and report to Traci Kyes, ViroCell’s Vice President of Business Development.

ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) Contract Development and Manufacturing Organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces that Farzin Farzaneh, PhD, Co-Founder and Chief Scientific Officer of ViroCell Biologics, will be hosting a panel event on Synthetic Biology at the annual Cell & Gene Therapy Meeting on the Mesa, to be held on 7-9 October 2024 in Phoenix, Arizona, US (full details below).

ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the completion of an oversubscribed convertible note offering. The oversubscription was led by new investor First Light Asset Management LLC, joining existing investors including Sartorius Stedim Biotech S.A. and Dorset Opportunity Fund LP.

ViroCell Biologics (“ViroCell” or the “Company”) a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the signing of a five-year Master Services Agreement (“MSA”) with a prominent U.S. NCI-designated cancer center.

ViroCell Biologics (“ViroCell” or the “Company”) announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy. In addition, Farzin Farzaneh, Ph.D., ViroCell’s Chief Scientific Officer, will be moderating a panel discussion at the conference. Both events will be livestreamed globally.

ViroCell Biologics (“ViroCell” or the “Company”), a specialist contract development and manufacturing organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces that the Company is now able to manufacture and globally export viral vectors from Great Ormond Street Hospital’s (GOSH) state-of-the-art manufacturing facility, the Zayed Centre for Research, for use in clinical trials. This follows the grant of a Manufacturer’s Authorisation License (MIA) to GOSH to manufacture viral vectors by the UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA).